Entegrion to develop blood product for U.S. Navy

08/26/2011 | MedCityNews.com

North Carolina biotech firm Entegrion is set to receive $9.84 million from the Navy for the development of a single blood product that has the potential to save lives on the battlefield. The product will combine two experimental blood products: Resusix, a freeze-dried human plasma designed to serve as an alternative to fresh-frozen plasma, and Stasix, a freeze-dried product based on blood platelets.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA